(3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine Dihydrochloride CAS 1062580-52-2 Purity >99.0% (GC) Tofacitinib Citrate Intermediate

Short Description:

Chemical Name: (3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine Dihydrochloride

CAS: 1062580-52-2

Purity: >99.0% (HPLC)

Chiral Purity (e.e.%): >99.0% (HPLC)

Appearance: White Solid

Intermediate of Tofacitinib Citrate (CAS: 540737-29-9)

Contact: Dr. Alvin Huang

Mobile/Wechat/WhatsApp: +86-15026746401

E-Mail: alvin@ruifuchem.com

Send email to us

Product Detail

Product Tags

1062580-52-2 - Description:

Shanghai Ruifu Chemical Co., Ltd. is the leading manufacturer of (3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine Dihydrochloride (CAS: 1062580-52-2) with high quality, intermediate of Tofacitinib Citrate (CAS: 540737-29-9). Ruifu Chemical has been supplying pharmaceutical intermediates and APIs, fine chemicals more than 15 years. Ruifu Chemical can provide worldwide delivery, competitive price, excellent service.
Purchase Tofacitinib Citrate Intermediates, please contact us by e-mail: alvin@ruifuchem.com

Intermediates of Tofacitinib Citrate:

Tofacitinib Citrate	CAS 540737-29-9
4-Chloropyrrolo[2,3-d]Pyrimidine	CAS 3680-69-1
4-Chloro-7-Tosyl-7H-Pyrrolo[2,3-d]Pyrimidine	CAS 479633-63-1
(3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine Dihydrochloride	CAS 1062580-52-2
(3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine	CAS 477600-70-7
2,4-Dichloro-7H-Pyrrolo[2,3-d]Pyrimidine	CAS 90213-66-4
(2R,3R)-2,3-Bis[(4-methylbenzoyl)oxy]butanedioic acid compd. with (3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine	CAS: 477600-71-8

1062580-52-2 - Chemical Properties:

Chemical Name	(3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine Dihydrochloride
Synonyms	cis-1-Benzyl-N,4-Dimethylpiperidin-3-Amine Dihydrochloride; (3R,4R)-cis-1-Benzyl-4-Methyl-3-(Methylamino)piperidine Dihydrochloride
Stock Status	In Stock, Regular Stock Quantity 500kgs
CAS Number	1062580-52-2
CAS Free Base	477600-70-7
Molecular Formula	C14H23ClN2
Molecular Weight	254.8 g/mol
Melting Point	249.0~251.0℃
Store Under Inert Gas	Store Under Inert Gas (Nitrogen or Argon) at 2-8℃
Storage Temperature	Store Long-Term in a Cool and Dry Place
COA & MSDS	Available
Origin of Product	Shanghai, China
Product Categories	Pharmaceutical Intermediates
Caution	Not For Human or Veterinary Use. For Research Use Only.
Brand	Ruifu Chemical

1062580-52-2 - Specifications:

Items	Specifications	Results
Appearance	White Solid	White Solid
Melting Point	249.0~251.0℃	249.0~251.0℃
Water by Karl Fischer	<0.50%	0.29%
Purity / Analysis Method	>99.0% (by HPLC Area)	99.9%
Chiral Purity (e.e.%)	>99.0% (by HPLC)	99.9%
1H NMR Spectrum	Conforms to Structure	Conforms
Mass Spectrum	Conforms to Structure	Conforms
Conclusion	The product has been tested and complies with the given specifications
Application	Intermediate of Tofacitinib Citrate (CAS: 540737-29-9)

1062580-52-2 - Package/Storage/Shipping:

Package: Fluorinated bottle, Aluminium foil bag, 25kg/cardboard drum, or according to customer's requirement.
Storage Condition: Keep the container tightly closed and store in a cool, dry (2~8℃), well-ventilated warehouse away from incompatible substances. Keep away from sunshine; avoid fire and heat sources; avoid moisture.
Shipping: Deliver to worldwide by air, by FedEx / DHL Express. Provide fast and reliable delivery.

1062580-52-2 - Advantages:

Sufficient Capacity: Sufficient facilities and technicians

Professional Service: One stop purchasing service

OEM Package: Custom package and label available

Fast Delivery: If within stock, three days delivery guaranteed

Stable Supply: Maintain reasonable stock

Technical Support: Technology solution available

Custom Synthesis Service: Ranged from grams to kilos

High Quality: Established a complete quality assurance system

1062580-52-2 - FAQ:

How to Purchase? Please contact Dr. Alvin Huang: sales@ruifuchem.com or alvin@ruifuchem.com

15 Years Experience? We have more than 15 years of experience in the manufacture and export of a wide range of high quality pharmaceutical intermediates or fine chemicals.

Main Markets? Sell to domestic market, North America, Europe, India, Korea, Japanese, Australia, etc.

Advantages? Superior quality, affordable price, professional services and technical support, fast delivery.

Quality Assurance? Strict quality control system. Professional equipment for analysis include NMR, LC-MS, GC, HPLC, ICP-MS, UV, IR, OR, K.F, ROI, LOD, MP, Clarity, Solubility, Microbial limit test, etc.

Samples? Most products provide free samples for quality evaluation, shipping cost should be paid by customers.

Factory Audit? Factory audit welcome. Please make an appointment in advance.

MOQ? No MOQ. Small order is acceptable.

Delivery Time? If within stock, three days delivery guaranteed.

Transportation? By Express (FedEx, DHL), by Air, by Sea.

Documents? After sales service: COA, MOA, ROS, MSDS, etc. can be provided.

Custom Synthesis? Can provide custom synthesis services to best fit your research needs.

Payment Terms? Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T (Telex Transfer), PayPal, Western Union, etc.

1062580-52-2 - Risk and Safety:

Hazard Class	IRRITANT
HS Code	2933322000

1062580-52-2 - Application:

(3R,4R)-1-Benzyl-N,4-Dimethylpiperidin-3-Amine Dihydrochloride (CAS: 1062580-52-2), intermediate of Tofacitinib Citrate (CAS: 540737-29-9). In November 2012, the US FDA approved Tofacitinib for the treatment of adult patients with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate. Tofacitinib is the first small molecule kinase inhibitor approved for the treatment of RA. Tofacitinib is an inhibitor of the four subtypes of Janus kinase (JAK): JAK1, JAK2, JAK3, and Tyk2. The JAKs are intracellular, nonreceptor tyrosine kinases that play important roles in the signal transduction pathway of many cytokines (e.g., interleukins 2, 4, 7, 9, 15, and 21) and are involved in the propagation of inflammation in RA. Tofacitinib acts by inhibiting the phosphorylation and activation of signal transducers and activators of transcription (STATs), thereby suppressing the production of inflammatory mediators in joint tissue.